Showing papers by "Hao Xie published in 2012"
TL;DR: Different classes of anticancer agents as emerging water contaminants, their occurrence in various waterbodies, the ecotoxicology, and the strategies for their treatment are reviewed.
Abstract: Anticancer agents as water contaminants belong to a general class of pharmaceuticals and personal care products as pollutants (PPCPs) that are widely present in the environment. They are less studied compared to other PPCPs in the past two decades. However, the cytotoxicity, genotoxicity, and endocrine disruption of these agents mar more concerning adverse effects on the environment and human health. Here, we review different classes of anticancer agents as emerging water contaminants, their occurrence in various waterbodies, the ecotoxicology, and the strategies for their treatment.
47 citations
8 citations
Journal Article•
TL;DR: RRM2 protein expression in pancreatic adenocarcinoma is neither prognostic nor predictive of adjuvant gemcitabine benefit in patients with resectable pancreaticAdenocARCinoma.
Abstract: Background
Ribonucleotide reductase M2 (RRM2) was associated with pancreatic tumor progression and resistance to gemcitabine. This study aimed to determine if RRM2 protein expression was prognostic in patients with resectable pancreatic adenocarcinoma and predictive of adjuvant gemcitabine benefit.
6 citations
TL;DR: The first reported case of extramammary Paget disease occurring in peristomal skin of a 61-year-old woman with ulcerative colitis is described, emphasizing the importance of recognizing such disease and the potential for associated neoplasia in patients with intestinal stomas.
5 citations
01 Jan 2012
TL;DR: RRM2 protein expression in pancreatic adenocarcinoma is neither prognostic nor predictive of adjuvant gemcitabine benefit in patients with resectable pancreaticAdenocARCinoma.
Abstract: Background: Ribonucleotide reductase M2 (RRM2) was associated with pancreatic tumor progression and resistance to gemcitabine. This study aimed to determine if RRM2 protein expression was prognostic in patients with resectable pancreatic adenocarcinoma and predictive of adjuvant gemcitabine benefit. Methods: 117 patients under- went tumor resection for pancreatic adenocarcinoma from 10/1999 to 12/2007. We constructed tissue microarrays from paraffin-embedded tumors and determined RRM2 protein expression using immunohistochemistry and grouped as negative or positive. We estimated overall survival (OS) and progression-free survival (PFS) using the Kaplan-Meier method and examined the prognostic and predictive value of RRM2 expression using Cox proportional hazards model. Results: RRM2 expression showed no prognostic value in the entire group regarding OS (median OS 30.9 months in RRM2-positive versus 13.7 months in RRM2-negative, P = 0.26) and PFS (median OS 20.6 months in RRM2-positive versus 11.8 months in RRM2-negative, P = 0.46). RRM2 expression did not predict adjuvant gemcit- abine benefit in the subgroup of 44 patients who received gemcitabine therapy (median OS 31.2 versus 15.2 months, P = 0.62; median PFS 11.3 versus 14.0 months, P = 0.35). Cox proportional hazards regression showed no prognostic effect of RRM2 expression on OS and PFS in the subgroup of 44 patients. However, the number of positive lymph nodes and perineural invasion were prognostic factors for OS (HR 1.2, P = 0.005) and for PFS (HR 5.5, P = 0.007), respectively. Conclusion: RRM2 protein expression in pancreatic adenocarcinoma is neither prognostic nor predictive of adjuvant gemcitabine benefit in patients with resectable pancreatic adenocarcinoma.
TL;DR: In this paper, cyclohexenes (III and VI) are synthesized by asymmetric copper-catalyzed Diels-Alder reactions between hydrazinodienes and N-acryloyl oxazolidinone dienophiles.
Abstract: Cyclohexenes (III) and (VII) are stereoselectively synthesized by asymmetric copper-catalyzed Diels—Alder reactions between hydrazinodienes and N-acryloyl oxazolidinone dienophiles.